imatinib mesylate has been researched along with Liver Dysfunction in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (70.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arakawa, H; Horike, SI; Kato, Y; Kawanishi, T; Meguro-Horike, M; Nishiuchi, T; Shengyu, D; Sugimoto, M | 1 |
| Borthakur, G; Cortes, J; Faderl, S; Kantarjian, H; O'Brien, S; Pierce, S; Ravandi, F; Rios, MB; Shan, J; Tong, WG | 1 |
| de Bruijn, P; Eechoute, K; Loos, WJ; Mathijssen, RH; Schiavon, G; Sleijfer, S; van der Bol, JM; Verweij, J | 1 |
| Ebihara, Y; Ito, Y; Kimura, Y; Kuriyama, Y; Miyazawa, H; Nakajima, A; Ohyashiki, K; Serizawa, H; Tauchi, T | 1 |
| Armbrust, T; Füzesi, L; Grabbe, E; Pieler, T; Ramadori, G | 1 |
| Ikuta, K; Inamura, J; Jimbo, J; Kohgo, Y; Miyokawa, N; Sato, K; Shindo, M; Tokusashi, Y; Torimoto, Y | 1 |
| Boccadoro, M; Campa, E; Dellacasa, C; Fava, C; Ferrero, D; Fumagalli, M; Mattioli, G; Perfetti, P; Pogliani, EM; Rege-Cambrin, G | 1 |
| Arai, A; Hayashi, S; Inazawa, J; Miura, O; Wakabayashi, S; Yan, W | 1 |
| Judson, IR | 1 |
| Belani, CP; Doroshow, JH; Egorin, MJ; Grem, JL; Hamilton, A; Hayes, MJ; Ivy, SP; LoRusso, PA; Mulkerin, DL; Murgo, AJ; Peng, B; Potter, DM; Ramanathan, RK; Remick, SC; Takimoto, CH | 1 |
1 review(s) available for imatinib mesylate and Liver Dysfunction
| Article | Year |
|---|---|
Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity.
Topics: Adult; Antineoplastic Agents; Benzamides; Biopsy; Chemical and Drug Induced Liver Injury; Chromosomes, Human, Pair 4; Chronic Disease; Exons; Female; Furosemide; Glucocorticoids; Heart Diseases; Heart Ventricles; Hepatocytes; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Introns; Liver Diseases; Lymphocytes; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Necrosis; Oncogene Proteins, Fusion; Piperazines; Prednisolone; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sequence Deletion; Sodium Potassium Chloride Symporter Inhibitors; Thrombosis | 2007 |
2 trial(s) available for imatinib mesylate and Liver Dysfunction
| Article | Year |
|---|---|
Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Kidney Diseases; Leukemia, Myeloid, Chronic-Phase; Liver Diseases; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2010 |
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bilirubin; Female; Gastrointestinal Diseases; Humans; Imatinib Mesylate; Liver Diseases; Liver Function Tests; Male; Middle Aged; Neoplasms; Piperazines; Pyrimidines | 2008 |
7 other study(ies) available for imatinib mesylate and Liver Dysfunction
| Article | Year |
|---|---|
Renal Pharmacokinetic Adaptation to Cholestasis Causes Increased Nephrotoxic Drug Accumulation by Mrp6 Downregulation in Mice.
Topics: Animals; Bile Ducts; Cholestasis; Cisplatin; Down-Regulation; Imatinib Mesylate; Kidney; Liver; Liver Diseases; Membrane Transport Proteins; Mice; Multidrug Resistance-Associated Proteins; Proteomics | 2023 |
Biliary excretion of imatinib and its active metabolite CGP74588 during severe hepatic dysfunction.
Topics: Aged; Antineoplastic Agents; Benzamides; Bile; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Diseases; Male; Piperazines; Pyrimidines; Severity of Illness Index | 2012 |
Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis.
Topics: Benzamides; Chemical and Drug Induced Liver Injury; Diagnosis, Differential; Female; Hepatitis, Viral, Human; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Diseases; Middle Aged; Piperazines; Pyrimidines | 2002 |
Successful treatment of hepatocellular carcinoma with the tyrosine kinase inhibitor imatinib in a patient with liver cirrhosis.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Hepatocellular; Humans; Imatinib Mesylate; Liver Cirrhosis; Liver Diseases; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2004 |
Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management.
Topics: Antineoplastic Agents; Benzamides; Biopsy; Chemical and Drug Induced Liver Injury; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver; Liver Diseases; Middle Aged; Piperazines; Prednisolone; Protein-Tyrosine Kinases; Pyrimidines | 2005 |
Corticosteroids can reverse severe imatinib-induced hepatotoxicity.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Benzamides; Chemical and Drug Induced Liver Injury; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver; Liver Diseases; Methylprednisolone; Piperazines; Prednisone; Pyrimidines | 2006 |
Imatinib for patients with liver or kidney dysfunction: no need to modify the dose.
Topics: Administration, Oral; Benzamides; Clinical Trials, Phase I as Topic; Drug Monitoring; Humans; Imatinib Mesylate; Kidney Diseases; Liver Diseases; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2008 |